AQUILA study, SEC improved disease activity, depression of PsA patients in both men and women. Women showed overall higher burden of disease. SEC effective up to 52 weeks with high treatment retention rates irrespective of gender @RheumNow #ACR21 Abst#1334 https://t.co/9cPGq5M648 https://t.co/iTrkRWoot0
Links:
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Pa…
https://bit.ly/31vhz4o
08-11-2021